We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The UK BioIndustry Association (BIA) and Informa Pharma Intelligence have published figures revealing a strong start to 2019 for venture capital investment in UK biotech, despite the uncertainties of Brexit.
Gene and cell therapy firm Oxford Biomedica is to invest £4 million to build digital and robotics capabilities that will help manufacture the next generation of cutting edge therapies.
Merck KGaA signs potential $1 billion deal with UK biotech, which further consolidating F-star’s growing reputation within the industry, only recently being named Life Science Innovation champion at Business Weekly Awards.